{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:47:33Z","timestamp":1789494453333,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pharma.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T20:54:30Z","timestamp":1643576070000},"page":"617-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Beta-blockers for the treatment of arrhythmias: Bisoprolol\u00a0\u2013\u00a0a systematic review"],"prefix":"10.1016","volume":"80","author":[{"given":"L.","family":"Muresan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cismaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Muresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gusetu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Puiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.O.","family":"Mada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharma.2022.01.007_bib0380","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S0025727300009455","article-title":"Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958\u20131978","volume":"50","author":"Quirke","year":"2006","journal-title":"Med Hist"},{"issue":"6","key":"10.1016\/j.pharma.2022.01.007_bib0385","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/08037051.2018.1527177","article-title":"2018 practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"27","author":"Williams","year":"2018","journal-title":"Blood Pressure"},{"issue":"17","key":"10.1016\/j.pharma.2022.01.007_bib0390","first-page":"e426","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0395","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0400","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pharma.2022.01.007_bib0405","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.pharma.2022.01.007_bib0410","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"10.1016\/j.pharma.2022.01.007_bib0415","first-page":"407","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.pdf","volume":"14","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.pharma.2022.01.007_bib0420","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.jacc.2014.07.017","volume":"64","author":"Fihn","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0425","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0430","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s12350-017-0917-9","volume":"24","author":"Patel","year":"2017","journal-title":"J Nucl Cardiol"},{"issue":"27","key":"10.1016\/j.pharma.2022.01.007_bib0435","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.pharma.2022.01.007_bib0440","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"issue":"11","key":"10.1016\/j.pharma.2022.01.007_bib0445","first-page":"1601","volume":"17","author":"Priori","year":"2015","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0450","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.pharma.2022.01.007_bib0455","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2015.09.019","volume":"67","author":"Page","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.pharma.2022.01.007_bib0460","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0465","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.pharma.2022.01.007_bib0470","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart rhythm"},{"issue":"1","key":"10.1016\/j.pharma.2022.01.007_bib0475","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.hrthm.2016.09.012","article-title":"Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent?","volume":"14","author":"Ackerman","year":"2017","journal-title":"Heart rhythm"},{"issue":"20","key":"10.1016\/j.pharma.2022.01.007_bib0480","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.jacc.2012.07.046","article-title":"Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol","volume":"60","author":"Chockalingam","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.pharma.2022.01.007_bib0485","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"Lopez-Sendon","year":"2004","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0490","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00606650","article-title":"Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris","volume":"31","author":"Dorow","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0495","first-page":"S167","article-title":"Electrophysiologic effects of an acute beta-blockade induced by bisoprolol in patients with supraventricular tachycardia as assessed by His-bundle electrograms","volume":"8","author":"Neuss","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0500","first-page":"S171","article-title":"Clinical evaluation of bisoprolol in the treatment of extrasystoles and sinus tachycardia: an interim report","volume":"8","author":"Sugimoto","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0505","first-page":"S46","article-title":"Comparison of bisoprolol with other beta-adrenoceptor blocking drugs","volume":"8","author":"Kramer","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0510","first-page":"S16","article-title":"Balanced pharmacokinetics and metabolism of bisoprolol","volume":"8","author":"Leopold","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0515","first-page":"200","article-title":"Pharmacodynamic profile of the selective beta 1-adrenoceptor antagonist bisoprolol","volume":"36","author":"Harting","year":"1986","journal-title":"Arzneimittel-Forschung"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0520","first-page":"S36","article-title":"Affinity and selectivity of beta-adrenoceptor antagonists in vitro","volume":"8","author":"Wellstein","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.pharma.2022.01.007_bib0525","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/00005344-198411000-00024","article-title":"Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs","volume":"6","author":"Schliep","year":"1984","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0530","first-page":"197","article-title":"Studies on the receptor profile of bisoprolol","volume":"36","author":"Klockow","year":"1986","journal-title":"Arzneimittel-Forschung"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0535","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1026180325278","article-title":"Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS)","volume":"17","author":"Czuriga","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 11","key":"10.1016\/j.pharma.2022.01.007_bib0540","first-page":"S21","article-title":"Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans","volume":"8","author":"Buhring","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2022.01.007_bib0545","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","article-title":"Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study","volume":"15","author":"Morales","year":"2017","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.pharma.2022.01.007_bib0550","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS investigators and committees","volume":"90","year":"1994","journal-title":"Circulation"},{"issue":"9146","key":"10.1016\/j.pharma.2022.01.007_bib0555","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"41","key":"10.1016\/j.pharma.2022.01.007_bib0560","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"issue":"7650","key":"10.1016\/j.pharma.2022.01.007_bib0565","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0740","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s004240000486","article-title":"Relationship between pulse interval and respiratory sinus arrhythmia: a time- and frequency-domain analysis of the effects of atropine","volume":"441","author":"Medigue","year":"2001","journal-title":"Pflugers Arch"},{"issue":"4","key":"10.1016\/j.pharma.2022.01.007_bib0695","first-page":"602","article-title":"Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial","volume":"19","author":"Katritsis","year":"2017","journal-title":"Europace"},{"issue":"16","key":"10.1016\/j.pharma.2022.01.007_bib0605","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/euhj.2000.2546","article-title":"Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs. bisoprolol","volume":"22","author":"Plewan","year":"2001","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.pharma.2022.01.007_bib0745","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1161\/01.CIR.103.10.1428","article-title":"Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial","volume":"103","author":"Lechat","year":"2001","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharma.2022.01.007_bib0610","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.amjcard.2003.07.009","article-title":"Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation","volume":"92","author":"Katritsis","year":"2003","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0650","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1536\/ihj.49.281","article-title":"Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation","volume":"49","author":"Ishiguro","year":"2008","journal-title":"Int Heart J"},{"issue":"6","key":"10.1016\/j.pharma.2022.01.007_bib0615","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1253\/circj.CJ-09-0989","article-title":"Comparative effects of carvedilol vs. bisoprolol for severe congestive heart failure","volume":"74","author":"Konishi","year":"2010","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0620","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2478\/v10153-011-0085-7","article-title":"Effect of selective beta-blockade with bisoprolol in the treatment of recent-onset atrial fibrillation","volume":"54","author":"Negreva","year":"2012","journal-title":"Folia medica"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0635","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2012.06.004","article-title":"Sinus rhythm versus atrial fibrillation in elderly patients with chronic heart failure\u00a0\u2013\u00a0insight from the cardiac insufficiency bisoprolol study in elderly","volume":"161","author":"Stankovic","year":"2012","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.pharma.2022.01.007_bib0630","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2013.02.010","article-title":"Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study","volume":"62","author":"Yamashita","year":"2013","journal-title":"J Cardiol"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0645","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00540-016-2199-9","article-title":"Switching therapy from intravenous beta-blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia","volume":"30","author":"Nakamura","year":"2016","journal-title":"J Anesth"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0640","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jjcc.2018.11.009","article-title":"Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent\/permanent atrial fibrillation (BISONO-AF study)","volume":"73","author":"Yamashita","year":"2019","journal-title":"J Cardiol"},{"issue":"8","key":"10.1016\/j.pharma.2022.01.007_bib0580","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1185\/030079906X115649","article-title":"Effect of prophylactic bisoprolol plus magnesium on the incidence of atrial fibrillation after coronary bypass surgery: results of a randomized controlled trial","volume":"22","author":"Behmanesh","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0575","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2008.06.034","article-title":"Postoperative oral amiodarone versus oral bisoprolol as prophylaxis against atrial fibrillation after coronary artery bypass graft surgery: a prospective randomized trial","volume":"137","author":"Sleilaty","year":"2009","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0570","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.amjcard.2010.08.062","article-title":"Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure","volume":"107","author":"Marazzi","year":"2011","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0585","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jtcvs.2012.06.042","article-title":"Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study","volume":"144","author":"Sezai","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"10.1016\/j.pharma.2022.01.007_bib0590","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s11748-019-01131-5","article-title":"Incidence of postoperative atrial fibrillation in transdermal beta-blocker patch users is lower than that in oral beta-blocker users after cardiac and\/or thoracic aortic surgery","volume":"67","author":"Okamura","year":"2019","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharma.2022.01.007_bib0595","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120907817","article-title":"Bisoprolol transdermal patch treatment for patients with atrial fibrillation after non-cardiac surgery: a single-center retrospective study of 61 patients","volume":"8","author":"Yasui","year":"2020","journal-title":"SAGE open medicine"},{"issue":"9","key":"10.1016\/j.pharma.2022.01.007_bib0720","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1253\/jcj.60.629","article-title":"Dipyridamole suppresses catecholamine- and Ca++ influx-sensitive ventricular arrhythmias","volume":"60","author":"Kobayashi","year":"1996","journal-title":"Japanese Circ J"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0725","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jjcc.2017.01.008","article-title":"Assessment of a novel transdermal selective beta1-blocker, the bisoprolol patch, for treating frequent premature ventricular contractions in patients without structural heart disease","volume":"70","author":"Shinohara","year":"2017","journal-title":"J Cardiol"},{"issue":"Suppl 5","key":"10.1016\/j.pharma.2022.01.007_bib0750","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1097\/00005344-199000165-00035","article-title":"Interaction of bisoprolol and procainamide in human cardiac impulse generation and conduction","volume":"16","author":"Verrostte","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0715","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/heartasia-2015-010675","article-title":"Effect of early bisoprolol administration on ventricular arrhythmia and cardiac death in patients with non-ST elevation myocardial infarction","volume":"7","author":"Maclean","year":"2015","journal-title":"Heart Asia"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0730","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/anec.12047","article-title":"Role of bisoprolol in patients with long QT syndrome","volume":"18","author":"Fazio","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0735","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10840-016-0161-2","article-title":"Experience with bisoprolol in long-QT1 and long-QT2 syndrome","volume":"47","author":"Steinberg","year":"2016","journal-title":"J Interven Card Electrophysiol"},{"key":"10.1016\/j.pharma.2022.01.007_bib0600","first-page":"CD004476","article-title":"Perioperative beta-blockers for preventing surgery-related mortality and morbidity","volume":"3","author":"Blessberger","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pharma.2022.01.007_bib0625","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1023\/B:CEPR.0000012389.01561.27","article-title":"Beta-blocker efficacy according to heart rate and rhythm in patients with heart failure. Commentary on the cardiac insufficiency bisoprolol study II analysis","volume":"7","author":"Lechat","year":"2003","journal-title":"Card Electrophysiol Rev"},{"issue":"4","key":"10.1016\/j.pharma.2022.01.007_bib0655","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","article-title":"Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis","volume":"28","author":"Nasr","year":"2007","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pharma.2022.01.007_bib0660","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jacc.2021.06.038","article-title":"Cryoballoon ablation as initial treatment for atrial fibrillation: JACC State-of-the-Art review","volume":"78","author":"Andrade","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.pharma.2022.01.007_bib0665","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2029554","article-title":"Cryoballoon ablation as initial therapy for atrial fibrillation","volume":"384","author":"Wazni","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharma.2022.01.007_bib0670","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1540-8159.2009.02428.x","article-title":"Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)\u00a0\u2013\u00a0study design","volume":"32","author":"Marrouche","year":"2009","journal-title":"Pacing Clin Electrophysiol"},{"issue":"14","key":"10.1016\/j.pharma.2022.01.007_bib0675","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.120.050991","article-title":"Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharma.2022.01.007_bib0680","doi-asserted-by":"crossref","first-page":"e007731","DOI":"10.1161\/CIRCEP.119.007731","article-title":"Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial","volume":"12","author":"Kuck","year":"2019","journal-title":"Circ Arrhythmia Electrophysiol"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0685","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.hlc.2018.10.022","article-title":"Catheter ablation versus medical therapy for atrial fibrillation in patients with heart failure: a meta-analysis of randomised controlled trials","volume":"28","author":"Virk","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.pharma.2022.01.007_bib0690","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10840-018-0349-8","article-title":"Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials","volume":"52","author":"Chen","year":"2018","journal-title":"J Interven Card Electrophysiol"},{"issue":"5","key":"10.1016\/j.pharma.2022.01.007_bib0700","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.amjcard.2018.05.009","article-title":"Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction","volume":"122","author":"Elgendy","year":"2018","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.pharma.2022.01.007_bib0705","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.4022\/jafib.2266","article-title":"Meta-analysis of catheter ablation versus medical therapy in patients with atrial fibrillation without heart failure","volume":"12","author":"Muhammad","year":"2020","journal-title":"J Atrial Fibrillation"},{"issue":"2","key":"10.1016\/j.pharma.2022.01.007_bib0710","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1067\/mhj.2002.120768","article-title":"Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies\u00a0\u2013\u00a0CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study","volume":"143","author":"Leizorovicz","year":"2002","journal-title":"Am Heart J"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450922000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:36:30Z","timestamp":1757720190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450922000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0003450922000074"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2022.01.007","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers for the treatment of arrhythmias: Bisoprolol\u00a0\u2013\u00a0a systematic review","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}